Development, Optimization, and Evaluation of Solid Lipid Nanoparticles of Celecoxib
Madhu Verma, Arun Nanda, Manish Gautam, Iti Chauhan, Mohd Yasir, Alok Pratap Singh, Sagarika Majhi, Raj Kumari, Meenakshi SharmaBackground:
In the present investigation, nano-lipid technology was exploited to control the release of celecoxib (CXB) and overcome its dissolution problem. Solid lipid nanoparticles (SLNs) have a small particle size (50-1000 nm) that results in a large surface area-to-volume ratio, which further enhances the contact between the drug and the dissolution medium. This leads to improved drug release and absorption.
Aim and Objective:
This study aimed to enhance the solubility and hence improve the therapeutic efficacy of a BCS Class-II drug-celecoxib formulating it as solid lipid nanoparticles.
Methods:
CXB-loaded-SLNs were prepared using the solvent emulsification-diffusion technique and optimized by CCD. Characterization included FTIR, drug loading, particle size, PDI, zeta potential, and in-vitro release and anti-inflammatory studies.
Results:
Optimized Formulation (OF1) exhibited particle size, PDI, and zeta potential were found to be 314 nm, 0.204, and -18.73 mV, respectively, with entrapment efficiency (79±0.18 %) and drug loading (44.38±0.21 %). The best-fitted model was the Korsemeyer-Peppas model, with drug release of 89.42 ±0.12 % in 24 h. OF1 formulation reduced the rat paw volume to a minimum (1±0.32) in 24 h when compared to pure API (2±0.62) and marketed preparation (2±0.42).
Conclusion:
OF1 demonstrated sustained drug release with enhanced solubility and better in-vivo anti-inflammatory studies compared to pure API.